Disease · MONDO_0008300
Comparisons in its trials25
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 25
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| DCCR vs Placebo for DCCR: deaths from any cause | 0 of 84 | 0 of 42 | 126 | NCT03440814 | Trial comparisons |
| DCCR vs Placebo for DCCR: serious adverse events | 6 of 84 | 0 of 42 | 126 | NCT03440814 | Trial comparisons |
Setmelanotide 1.5 mg (Open-Label Extension) vs Setmelanotide 2.5 mg (Open-Label Extension): Number of Participants With Clinically Significant Percent Change From Baseline in Body Mass Measured Using DEXA - Period 4 | 0 of 19 | 0 of 20 | 39 | NCT02311673 | Trial comparisons |
Setmelanotide 1.5 mg (Open-Label Extension) vs Setmelanotide 2.5 mg (Open-Label Extension): Number of Participants With Clinically Significant Percent Change From Baseline in Body Fat Measured Using DEXA - Period 4 | 0 of 19 | 0 of 20 | 39 | NCT02311673 | Trial comparisons |
| Carbetocin (FE 992097) vs Placebo: deaths from any cause | 0 of 17 | 0 of 20 | 37 | NCT01968187 | Trial comparisons |
| Carbetocin (FE 992097) vs Placebo: serious adverse events | 0 of 17 | 0 of 20 | 37 | NCT01968187 | Trial comparisons |
| Experimental: Intranasal Oxytocin (IN-OXT) vs Placebo Comparator: Matched Placebo: deaths from any cause | 0 of 15 | 0 of 17 | 32 | NCT03197662 | Trial comparisons |
| Experimental: Intranasal Oxytocin (IN-OXT) vs Placebo Comparator: Matched Placebo: serious adverse events | 0 of 15 | 0 of 17 | 32 | NCT03197662 | Trial comparisons |
| Intranasal Oxytocin (IN-OXT) vs Matched Placebo: deaths from any cause | 0 of 11 | 0 of 12 | 23 | NCT02629991 | Trial comparisons |
| Intranasal Oxytocin (IN-OXT) vs Matched Placebo: serious adverse events | 0 of 11 | 0 of 12 | 23 | NCT02629991 | Trial comparisons |
| Intranasal Oxytocin vs IN-placebo: deaths from any cause | 0 of 10 | 0 of 5 | 15 | NCT03245762 | Trial comparisons |
| Intranasal Oxytocin vs IN-placebo: serious adverse events | 0 of 10 | 0 of 5 | 15 | NCT03245762 | Trial comparisons |
| GH Naive Pediatric Cohort vs GH Treated Pediatric Cohort: Bone Maturation | 4 of 6 | 0 of 7 | 13 | NCT04697381 | Trial comparisons |
| Cannabidiol vs Placebo: deaths from any cause | 0 of 4 | 0 of 3 | 7 | NCT02844933 | Trial comparisons |
| Cannabidiol vs Placebo: serious adverse events | 0 of 4 | 0 of 3 | 7 | NCT02844933 | Trial comparisons |
| Octreotide vs Placebo Comparator: Number of Participants With Decreased Body Composition From Baseline to 6 Months by BOD POD® | 2 of 2 | 3 of 3 | 5 | NCT00399893 | Trial comparisons |
| Octreotide vs Placebo Comparator: Number of Participants With Improved Leptin Regulation From Baseline to 6 Months | 1 of 2 | 2 of 3 | 5 | NCT00399893 | Trial comparisons |
| Octreotide vs Placebo Comparator: Number of Participants With Improved Insulin Regulation From Baseline to 6 Months | 2 of 2 | 0 of 3 | 5 | NCT00399893 | Trial comparisons |
| Octreotide vs Placebo Comparator: Number of Participants With Decreased BMI Z-score From Baseline to 6 Months | 0 of 2 | 2 of 3 | 5 | NCT00399893 | Trial comparisons |
| Octreotide vs Placebo Comparator: Number of Participants With Decrease in Fasting Total Ghrelin | 1 of 2 | 1 of 3 | 5 | NCT00399893 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0008300/comparisons